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osting by EAbstract Background: Granulocyte-colony stimulating factor (G-CSF) is a lineage-restricted
hematopoietic growth factor. It induces proliferation and maturation of neutrophilic precursors
and progenitors and activates neutrophil functions. It is used to ameliorate or prevent profound
neutropenia and its consequences. G-CSF therapy in neutropenic disorders increases neutrophil
count and improves infectious complications. However, it is not without side effects. Here, we dis-
cuss the case of a 2 years old patient with Kostmann’s disease who developed cataracts following
high-dose G-CSF therapy. We also review the relevant literature on G-CSF-related complications.
ª 2010 King Saud University. All rights reserved.1. Introduction
Granulocyte-colony stimulating factor (G-CSF) is a lineage-
restricted hematopoietic growth factor that can induce prolif-
eration, maturation and activation of neutrophils and their
progenitors. Other cells like stromal and endothelial cells can
also be activated (Bodey et al., 1966; Morstyn et al., 1988; Tril-
let-Lenior et al., 1993). G-CSF has been used to ameliorate
and prevent profound neutropenia and its consequences. It ismatology Department, King
, P.O. Box 80215, Post Code
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ity. All rights reserved. Peer-
d University.
lsevieralso used to enhance mobilization of peripheral blood progen-
itor cells for bone marrow transplantation, and accelerate
reconstitution after both allogeneic and autologous bone mar-
row transplantation (British Society for Hematology, 2003).
Congenital neutropenia, such as Kostmann’s or Schwach-
mann-Diamond syndrome, are associated with severe neutro-
penia, which causes serious infectious complications that can
be life threatening. G-CSF therapy has been approved for
these disorders, as it has been found to increase the number
of circulating neutrophils and improve infectious complica-
tions (Jakubowski et al., 1989).
2. Case report
A Yemeni boy was delivered normally to a 23-years-old
mother with normal birth weight and Apgar scores. At birth,
his examination was unremarkable and blood count was nor-
mal. He exhibited normal growth and development, had no
history of any medications and received up-to-date vaccina-
tions. His parents are ﬁrst degree cousins and he has an
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history of congenital or inherited disorders.
At the age of 7 months, he presented with high grade fever
for 20 days and diarrhea for 1 week. There was no focus of
infection, lymphadenopathy or organomegaly. Laboratory re-
sults showed persistent severe neutropenia with an absolute
neutrophil count of 0.1 · 109/L and iron deﬁcient anemia.
The blood ﬁlm conﬁrmed severe neutropenia and revealed reac-
tive lymphocytes; no blasts or dysplastic leukocytes were ob-
served. Renal and liver function tests were normal. Blood
sugar and electrolytes were within normal ranges. A septic
screen was negative and a virology screen for HIV 1 and 2, par-
vovirus, and Epstein Bar virus antibodies was negative. The pa-
tient was positive for cytomegalovirus (CMV) IgG and IgM.
The mother was negative for CMV antibodies. Septic screen
was negative. CMV IgG and IgM levels remained positive.
The patient received ceftriaxone (weight adjusted dose) and
oral paracetamol as an antipyretic, and showed improvement.
After being stabilized, he was discharged on oral penicillin
for 10 days and a daily oral iron supplement. At discharge,
his absolute neutrophil count was 0.68 · 109/L. One month la-
ter, he was admitted again with fever and cough. Examination
revealed congested and enlarged tonsils, which were removed
surgically. Histology revealed evidence of a chronic inﬂamma-
tory process with no evidence of lymphoma. Laboratory tests
showed persistent neutropenia of 0.2 · 109/L. The patient re-
sponded to intravenous antibiotics (cephalosporins).
Bone marrow aspiration was consistent with a diagnosis of
Kostmann’s disease. Immunophenotypic analysis of his lym-
phocyte proﬁle revealed normal levels of T, B and natural kill-
er lymphocytes. The patient had normal immunoglobulin
levels with a normal count and ratio of CD4 and CD8 cells.
Both parents and the brother were tested and had normal neu-
trophil counts and neutrophil morphology.
After conﬁrming the diagnosis, the patient was started on
Filgrastim (recombinant methionyl human G-CSF) at a dose
of 5 lg/kg (mcg/kg) body weight subcutaneous (sc) on a daily
basis during hospital admission periods, which usually lasted
7–10 days. Upon discharge, the patient received G-CSF
5 mcg/kg sc 1–2 times weekly for 10 weeks, with no apparent
effect on neutrophil count. The dose was increased to
15 mcg/kg weekly for 5 weeks, again with no increase in neu-
trophil count, although episodes of febrile illness and hospital
admissions were minimized. The patient was shifted back to a
dose of 5 mcg/kg body weight once weekly for 3 months.
Granulocyte monocyte (GM)-CSF at a dose of 5 mcg/kg sc
was administered on three occasions when G-CSF was not
available. Neutrophil count remained in the range of 0.3–
0.5 · 109/L.
Four months after the initiation of high-dose G-CSF, the
patient developed bilateral eye cataracts, more severely in the
left eye, which required left lensectomy. Lens histology re-
vealed chronic inﬂammation, many macrophages and some
ﬁbrosis. Cultures of the lens tissue were negative for bacteria,
viruses and fungi. G-CSF was stopped, and the patient was put
on prophylactic oral penicillin with close follow up. However,
he was admitted on two occasions with respiratory tract infec-
tions treated as per febrile neutropenia protocol.
At the most recent clinical visit, a full blood count revealed
a white cell count of 6 · 109/L with an absolute neutrophil
count of 0.2 · 109/L; 10% monocytes; and 76% lymphocytes.
Platelet count was 296 · 109/L and hemoglobin was 11.4 g/dL.A blood ﬁlm showed no evidence of dysplasia and no blasts
were noted. The family was counseled for stem cell transplan-
tation. Therefore, patient and family moved back to their ori-
ginal country in order to arrange for transplantation and we
lost contact with them. In terms of medication history, the pa-
tient did not receive any steroid therapy and never received
non-steroidal anti-inﬂammatory drugs (NSAIDs). In addition
to regular doses of G-CSF and intravenous antibiotics for neu-
tropenia-related febrile illnesses during in-patient admissions,
he was on regular prophylactic doses of oral penicillin, oral
iron supplement and oral paracetamol, as required.3. Discussion and literature review
Cataract is a term used for opacity of the lens that affects vi-
sual acuity. The pathology of cataracts involves enhanced pro-
tein carbonylation and glycation in the epithelial cells of the
lenses of affected individuals (Balog et al., 2001). The most
common causes of cataract are age, trauma, inﬂammation,
metabolic and nutritional defects, corticosteroid therapy and
radiation damage (Berson, 1993). Cataracts are increasingly
reported in long-term survivors, particularly children, of bone
marrow transplantation who received full-body irradiation
prior to transplantation. In one study, cataracts occurred in
20% of children who were recipients of a bone marrow trans-
plant (Barrett et al., 1987).
Kostmann’s disease is a rare autosomal recessive disorder
characterized by severe neutropenia that was ﬁrst described
by Kostmann in 1956 (Kostmann, 1956). Its prevalence is esti-
mated to be 1–2 cases per million individuals. The disease is
characterized by an absolute neutrophil count typically less
than 0.2 · 109/L. The mortality rate of Kostmann’s disease
can be as high as 70% or higher within the ﬁrst year of life
in the absence of therapy, mainly due to bacteremia or septice-
mia, most commonly from streptococci, staphylococci, Pseu-
domonas and fungi (Baehner and Miller, 1995). Recently,
intervention with G-CSF and hematopoietic stem cell trans-
plantation has been shown to signiﬁcantly improve clinical
outcomes in patients with Kostmann’s disease (Dale et al.,
2003), although cases of severe congenital neutropenia that is
unresponsive to G-CSF have been reported (Ryan et al.,
1995; Dale et al., 1993; Imashuku et al., 1992).
The underlying etiology of Kostmann’s disease is unknown,
although defects in G-CSF-induced intracellular signal trans-
duction have been implicated. A genetic defect a region of
chromosome 1 (1p35–p34.3) that corresponds to the G-CSF
receptor coding region has been reported (Dror and Sung,
2004). Using a positional cloning approach and candidate gene
evaluation, a homozygous germline mutation in HAX1 in
many pedigrees of Kostmann’s disease was recently identiﬁed.
HAX1 encodes the mitochondrial protein HS1-associated pro-
tein X-1 (HAX1), which functions in signal transduction and
cytoskeletal regulation. HAX1 is critical for maintaining the
inner mitochondrial membrane potential and protecting
against apoptosis in myeloid cells. Defects in HAX1 have been
shown to depress apoptosis, underscoring the importance of
apoptosis in neutrophil development (Klein et al., 2006).
Currently, the mainstay of therapy for severe congenital
neutropenia/Kostmann’s syndrome is recombinant human
(rHu)G-CSF. Treatment with rHuG-CSF results in increased
granulocyte count within 7–10 days of administration, and is
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symptoms, including fever and infections (Bonilla et al.,
1989). The dose required is variable, but the commonly used
dose for congenital neutropenia is 2–5 lg/kg/day (Sieff,
1990). Escalating doses are used if the patient is non-respon-
sive (Ryan et al., 1995; Smith et al., 1995; Soylu et al., 1999).
G-CSF is well tolerated in acute sittings. A small number of
patients experience therapy related bone pain, and high-doses
of G-CSF can cause fever, rashes, pericarditis, pleural effusion,
thrombocytopenia, splenomegaly, and vasculitis, particularly
with chronic use. Osteopenia/osteoporosis has been reported
in 14% of patients receiving G-CSF for long periods (Dale
et al., 2006). Management of G-CSF side effects usually
involves discontinuation of the drug and administration of
supportive therapy as needed, such as pain control or anti-
pyretics.
Cataracts associated with elevated G-CSF have been
reported in experimental animals. Mice carrying a murine
GM-CSF transgene under the control of a retroviral pro-
moter exhibit elevated levels of GM-CSF in serum, urine,
peritoneal cavity, and eye. The eyes of these transgenic mice
are opaque, contain accumulations of macrophages, and ex-
hibit retinal damage. The GM-CSF transgene in these mice
was expressed in peritoneal cells as well as in eyes and inﬁl-
trated striated muscle (Lang et al., 1987). In a study involving
54 patients with severe congenital neutropenia on long-term
(4–6 years) G-CSF therapy, a single case of cataracts that
may or may not have been due so treatment was reported
(Bonilla et al., 1994).
Acute myeloid leukemia or myelodysplasia may develop in
approximately 10% of patients with Kostmann’s disease,
which suggests that Kostmann’s is a pre-leukemic syndrome
(Whetton, 1991). Chronic or prolonged use of G-CSF can in-
duce myelodysplastic syndrome and acute myeloid leukemia
(MDS/AML), and add to an existing risk of leukemic progres-
sion (Weinblatt et al., 1995; Tidow et al., 1997). In patients
with severe congenital neutropenia on long-term G-CSF ther-
apy, the risk of developing MDS/AML increases signiﬁcantly
with time. In one report, the cumulative incidence of MDS/
AML was estimated to be 21% after 10 years on G-CSF ther-
apy and 36% after 12 years. The dose of G-CSF also appears
to be signiﬁcantly and positively associated with risk of MDS/
AML. In patients who required 6 mcg/kg/day or more, the risk
of developing MDS/AML was 2.5 fold higher than patients
who required less than 6 mcg/kg/day (Freedman et al., 1996;
Ancliff et al., 2003; Rosenberg et al., 2006).
Our patient was diagnosed with severe congenital neutrope-
nia based on full blood count, blood ﬁlm, bone marrow anal-
ysis and exclusion of other causes of neutropenia. He had a
severe course that required several major care hospital admis-
sions for management of febrile neutropenia episodes. He was
treated with regular granulocyte growth factors injections, the
frequency and doses of which varied. However, despite receiv-
ing relatively large doses of G-CSF, the patient did not re-
spond. Subsequently, the child developed cataracts. There
was no history of eye trauma or radiation exposure. Also,
the patient had no known metabolite or nutritional deﬁciencies
apart from iron deﬁciency anemia, which was treated with iron
supplementation therapy. While cataracts are a well-known
side effect of corticosteroid therapy (Urban and Cotlier,
1986), there have been no reports in the literature of cataracts
associated with colony stimulating factor therapy. Of note, ourpatient had no history of receiving steroid medication or
NSIDS. Thus, cataracts appear to be a rare adverse effect of
G-CSF treatment that may have been dose-related in this
patient, since it manifested after the patient received a course
of high-dose G-SCF therapy. However, we cannot completely
rule out other possible causes that are unrelated to G-CSF
therapy. In this regard, we note that the patient was positive
for CMV Immunoglobulins. CMV infection of the eye causes
CMV retinitis, a sight-threatening disease characterized by
inﬂammation of the retina. CMV retinitis is most commonly
associated with immunosuppression (e.g. individuals infected
with HIV), and steroid use, neither of which is applicable in
this case (Yust et al., 2004; Deayton et al., 2000). In addition,
lens tissue cultures were negative.
Granulocyte growth factor therapy was stopped when the
cataracts became apparent. A lensectomy was performed and
the patient was put on prophylactic oral antibiotic therapy
with close clinical monitoring. Other serious complications of
G-CSF, particularly pericarditis, pleural effusion, thrombocy-
topenia, vasculitis, rashes and splenomegaly were not identi-
ﬁed in our patient. The only other related complication
found was osteopenia. The family underwent counseling for
hematopoietic stem cell transplantation. Although the patient
showed no symptoms or sings of MDS/AML transformation
at that time, stem cell transplantation was recommended as
the patient was not responsive to granulocyte growth factors
therapy, and because of the anticipated risk of leukemogenesis
and myelodysplasia with G-CSF therapy.
4. Conclusion
G-CSF is an approved ﬁrst-time therapy for severe chronic
neutropenia. It greatly improves the patient’s quality of life
by markedly reducing the occurrence of infections, and the
need for hospitalizations and medications. Complications of
G-CSF include fever, rashes, pericarditis, pleural effusion,
splenomegaly, vasculitis and osteoporosis. Cataracts are a rare
side effect of G-CSF and may possibly be dose-related. More
serious side effects, such as acute leukemia and myelodyspla-
sia, are beginning to be reported more frequently. Regular
evaluation of patients receiving G-CSF is mandatory.Acknowledgments
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